Clinical characterization and natural history of chemotherapy‐induced dilated cardiomyopathy

• Published in: ESC Heart Failure Vol. 9; no. 5; pp. 3052 - 3059
• Main Authors: Lalario, Andrea, Del Mestre, Eva, Lo Casto, Michele, Nuzzi, Vincenzo, Manca, Paolo, Bromage, Daniel I., Barbati, Giulia, Merlo, Marco, Sinagra, Gianfranco, Cannatà, Antonio
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.10.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antineoplastic Agents; Arrhythmias, Cardiac - complications; Breast cancer; Cancer therapies; Cardiac arrhythmia; Cardiomyopathy; Cardiomyopathy, Dilated - chemically induced; Cardiomyopathy, Dilated - diagnosis; Cardiomyopathy, Dilated - epidemiology; Cardiotoxicity; Cardiovascular disease; Chemotherapy; Chemotherapy induced cardiomyopathy; Dilated cardiomyopathy; Ejection fraction; Heart; Heart Transplantation; Humans; Lymphoma; Medical prognosis; Missing data; Mortality; Original; Outcomes; Population; Prognosis; Radiation therapy; Stroke Volume; Variables; Ventricular Function, Left - physiology; Prognosis; Cardiotoxicity; Dilated cardiomyopathy; Chemotherapy induced cardiomyopathy; Outcomes

Aims Chemotherapy‐induced dilated cardiomyopathy (CI‐DCM) is a well‐recognized phenotype of non‐ischemic dilated cardiomyopathy (DCM), characterized by poor outcomes. However, a detailed comparison between idiopathic DCM (iDCM) and CI‐DCM is still lacking. Methods and results All consecutive DCM pat...